CPHI Americas 2025: Driving Innovation with BioDuro
In this interview with The Pharma Navigator, Kevin Li from BioDuro, a global CRDMO, reveals what he is looking forward to most and what the company will be showcasing at this year’s CPHI Americas event.
Over recent years, bio/pharmaceutical companies have been investigating increasingly complex molecules to treat the rising cases of chronic diseases, affecting the aging global population. However, these molecules are notoriously difficult to handle and costly to develop, leading to a greater need for specialist expertise, capabilities, and capacity to be able to successfully and efficiently bring these promising options to market.
To access specialist expertise and capacity, bio/pharma companies commonly seek out service-provider partners to perform development and manufacturing functions or even research functions (1). When using multiple partners to perform the various functions required for a complex project, however, there are risks to timelines and costs as appropriate quality systems need to be implemented and tech transfer needs to be performed between each provider.
As a result, fully integrated offerings, whereby a contract research, development, and manufacturing organization (CRDMO) provides all necessary services under one roof, are becoming a popular choice. In fact, according to market research, the CRDMO market is forecast to experience growth at a compound annual rate of 11.3% between 2024 and 2031, reaching USD 266.7 billion (2). For this interview, The Pharma Navigatorspoke with Kevin Li, MBA, Chief Marketing Officer, BioDuro, to learn more about what the company is looking forward to at CPHI Americas.
Excited to Engage
TPN: What is BioDuro most looking forward to at CPHI Americas this year?
Li: At BioDuro, we’re thrilled to join our global peers and partners at CPHI Americas 2025. This event offers a premier platform to highlight the strength of our fully integrated drug discovery, development, and manufacturing solutions. While our expertise in small molecules remains a cornerstone, we’re especially excited to engage in forward-looking conversations around emerging modalities — particularly antibody-drug conjugates (ADCs), peptides, and beyond.
TPN: Are there any innovations that BioDuro will be showcasing at this year’s event?
Li: Yes, we’re excited to unveil our new drug substance manufacturing campus, designed to support projects from preclinical development all the way through to commercial-scale production. In addition, we are also excited to share our new capabilities in high-potency API (HPAPIs), as well as scale-up capacity for peptides and peptide-drug conjugates.
For biotech startups seeking faster, more cost-effective solutions for early-phase programs, we’re excited to share case studies where our custom-designed platforms — combining drug substance, drug product, and drug metabolism and pharmacokinetics (DMPK) services — enabled clients to rapidly advance to investigational new drug (IND) filing.
TPN: Where can visitors find BioDuro at CPHI Americas?
Li: Visitors can find our team at Booth #917. We welcome attendees to stop by for expert insights, partnership opportunities, and a look at how we’re driving innovation across the drug development spectrum.
References
BioDuro. Uncovering the CRDMO Advantage in Drug Development. Insights, Jan. 19, 2025.
Insight Ace Analytic. Pharmaceutical CRDMO Services Market Size, Share & Trends Analysis Report by Type (Small molecular CRDMO service, Middle molecular CRDMO service, Large molecular CRDMO service, by Application (Oncology, Central Nervous System (CNS), Cardiovascular, Infectious Diseases, Hematology, Vaccine), by Region, and by Segment Forecasts, 2024–2031. Market Research Report, August 2024.
Photo by JESHOOTS.COM on Unsplash